TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 75 years admitted to a general medicine or surgical services.~* A known history of type 2 diabetes mellitus \> 3 months, receiving either diet alone, oral monotherapy, or with any combination of oral antidiabetic agents (sulfonylureas, meglitinides, metformin, thiazolidinediones, dipeptidyl peptidase (DPP) IV inhibitors).~* Patients admitted for non-cardiac elective or emergency surgery or trauma.~* Subjects must have an admission BG \> 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate \< 18 milliequivalent /L, potential hydrogen (pH) \< 7.30, or positive serum or urinary ketones).~Exclusion Criteria:~* Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).~* Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria \[32\].~* Patients with acute critical or surgical illness admitted to the ICU or expected to require admission to the ICU.~* Patients admitted for coronary artery bypass graft (CABG) or patients receiving continuous insulin infusion.~* Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3.0 mg/dl).~* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~* Female subjects are pregnant or breast feeding at time of enrollment into the study.~* Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.~* Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Basal Plus Regimen (Type: EXPERIMENTAL): glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
- Basal Bolus (Type: EXPERIMENTAL): glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
- sliding scale regular insulin (SSRI) (Type: ACTIVE_COMPARATOR): sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a diagnosis of idiopathic PD according to United Kingdom Parkinson's Disease Brain Bank Criteria~* mMIDI ≥ 3 score with ICD~* Patients must be on an anti-parkinson treatment at least 6 months before screening.~* for this protocol, dopamine agonists should be included in his/her anti-parkinson treatment.~* 30years ≤ patients \< 80years of age, male or female~* patients must give written informed consent before any assessment is performed~Exclusion Criteria:~* Requirement of treatment with serious cognitive disorder, behavioral disorder, or mental illness currently or in the future~* for the patients ≤ 65years: K-MMSE(korean version of Mini-Mental State Exam) ≤24, or for the patients ≥ 66years: K-MMSE ≤ 20, or the patients have dementia(incl. early dementia) even though K-MMSE score is more than 20~* Requirement of treatment more than 6times per day due to the severe motor fluctuation.~* Severe dyskinesia~* DBS(Deep Brain Stimulation)or any other surgical treatment~* History of melanoma or not-diagnostic skin trouble/skin lesions~* narrow angle glaucoma~* clinically serious surgical or medical condition~* malignant tumor~* use of other investigational drugs at the time of enrollment within 4weeks~* pregnant, nursing or lactating women~* women of child-bearing potential~* history of hypersensitivity or allergy to levodopa/carbidopa~* any serious disease according to the investigator's discretion

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Levodopa/Carbidopa(200mg/50mg) (Type: EXPERIMENTAL): None
- Control A (dopaminergic agonist ) (Type: EXPERIMENTAL): Parkinson patients treated with anti-Parkinson drug over 6 months.
- Control B (no drug) (Type: NO_INTERVENTION): Parkinson diseased patients not treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* being afebrile,~* willing to participate in the trial, and~* the ability to swallow oral medications.~Exclusion Criteria:~* a presence of an acute febrile illness or severe illness that impairs the ability to take oral medication~* HIV-positive child receiving cotrimoxazole prophylaxis,~* a child who has received a dose of antimalarial drug including dihydroartemisinin-piperaquine during the past month; and~* a history of allergy to DHA-PQ.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine will be administered to the intervention arm
- Control (Type: NO_INTERVENTION): Individuals that will get malaria infection and present at the health facility with clinical signs and symptoms will be treated according to the Tanzania National Malaria Treatment guidelines using artemether-lumefantrine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must have understood and voluntarily signed the informed consent and privacy form.~2. Age ≥ 18 years at the time of signing the informed consent and privacy form.~3. Patients with available hospital medical chart since the start of apremilast treatment ('index date').~4. Diagnosis of plaque psoriasis.~5. Treatment with apremilast for plaque psoriasis, according to Summary of Product Characteristics (SmPC), started 6 (±1) months before enrollment. Patients who interrupted apremilast treatment before enrollment will also be included.~6. Ability to understand (read \& write) the Italian language and to follow the study instructions.~Exclusion Criteria:~1. Refusal to participate in this study or current participation in the treatment phase of an interventional clinical trial.~2. Started apremilast as part of a clinical trial, or previous apremilast use (prior to the index date).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key eligibility criteria:~* Post-menarchal females, aged 12 years or more~* Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms: presence of white to grey homogeneous discharge; positive whiff test indicating an amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5; and presence at least 20% clue cells of total epithelial cells~* Nugent score of at least 4~* Otherwise healthy, as determined by medical history, physical examination~* normal Pap smear at or documented within 24 months of screening

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VivaGel (Type: EXPERIMENTAL): None
- HEC Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma not amenable to local therapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* At least one measurable lesion~* Adequate organ function~Exclusion criteria:~* Prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-PD ligand-1 (PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agent~* Is currently participating or has participated in a study with an investigational compound or device within 30 days, or 5X half-life of the investigational compound, whichever is longer, of initial dosing on this study~* Chemotherapy, targeted small molecule therapy, radiotherapy, or biological cancer therapy (including monoclonal antibodies) within 4 weeks prior to the first dose of trial treatment, or not recovered (\<= Grade 1 or baseline) from adverse events due to a previously administered agent~* Expected to require any other form of systemic or localized antineoplastic therapy while in study~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents~* Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week prior to the first dose of study treatment~* Received a live vaccine within 4 weeks prior to the first dose of trial treatment~* Has a known hypersensitivity to the components of the study drug or another monoclonal antibody~* History or evidence of active pneumonitis~* Human immunodeficiency virus (HIV)-positive~* Has known history of active Hepatitis B or C~* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial treatment through 120 days after the last dose of study medication

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced Cutaneous Melanoma (Type: EXPERIMENTAL): Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
- Advanced Mucosal Melanoma (Type: EXPERIMENTAL): Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Superficial, Cervical Block in Thyroid Surgery, a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Elective thyroid or combined thyroid/parathyroid surgery, restricted to the central cervical compartment~* Informed consent~Exclusion Criteria:~* Intolerance to used medication~* Recurrent disease~* Neck dissection, sternotomy~* Emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cervical block before surgery (Type: EXPERIMENTAL): bilateral superficial cervical block, placed before surgery (just before skin incision)
- placebo cervical block before surgery (Type: PLACEBO_COMPARATOR): placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
- cervical block after surgery (Type: EXPERIMENTAL): bilateral superficial cervical block, placed after surgery (just after skin closure)
- placebo cervical block after surgery (Type: PLACEBO_COMPARATOR): placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with dyspnea (difficulty breathing and shortness of breath) at rest, while supine, or immediately upon minimal activity such as talking, eating, or bathing~* having evidence of heart disease, rather than pulmonary disease, as the primary cause for the dyspnea (by demonstrating at least two of the following: jugular venous distension, paroxysmal nocturnal dyspnea or 2-pillow orthopnea within 72 hours before the start of study drug, abdominal discomfort due to hepatosplanchnic congestion, chest x-ray with findings indicative of heart failure)~* having elevated cardiac filling pressures either by clinical estimate in non-catheterized patients, or a measured pulmonary capillary wedge pressure (PCWP) \>= 20 mm Hg in catheterized patients~* requiring hospitalization and intravenous therapy for at least 24 hours for the treatment of acutely decompensated heart failure.~Exclusion Criteria:~* NPatients having systolic blood pressure consistently less than 90 mm Hg~* having cardiogenic shock (a sudden decrease in blood pressure that results in decreased perfusion of body tissues and organs), volume depletion, or any other clinical condition that would contraindicate the administration of an intravenous agent with potent vasodilating properties~* having their most recent pulmonary capillary wedge pressure (PCWP) \< 20 mm Hg within 24 hours before randomization~* having a clinical status so acutely unstable that the potential subject could not tolerate placement of a right heart catheter or the 3-hour placebo period~* unable to have intravenous nitroglycerin withheld (e.g., intravenous nitroglycerin for management of an acute coronary syndrome).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): nesiritide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed study drug treatment in parent study (VX18-445-106 Part B, NCT03691779), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study~Key Exclusion Criteria:~* History of study drug intolerance in parent study~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Combination Arm (Type: EXPERIMENTAL): Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PEEP Mask for Tracheobronchomalacia-Induced Cough

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Visualization of ≥50% collapse of the trachea or mainstem bronchus on CT scan or bronchoscopy~* No upper or lower respiratory infection within 4 weeks~* Having capacity to provide legal written informed consent~Exclusion Criteria:~* History of tracheobronchoplasty or chronic tracheal stenting~* Current tracheostomy~* History of external chest trauma~* History of:~  * Active treatment for Lung cancer~ * Lung transplantation~ * Unstable congestive heart failure~ * History of spontaneous pneumothorax~* Other medical conditions that interfere with participation in the study~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nPEP Recipients (Type: EXPERIMENTAL): Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of reproductive age from 18 to 45 years~* Must be choosing LNG-IUC for contraception~* Must be English-speaking~* Be willing to avoid additional use of exogenous hormones, such as oral contraceptives, for the duration of the study~* Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as ibuprofen or aspirin for the duration of the study~* Be willing to comply with the study protocol, keep the bleeding diary and comply with follow-up visits and telephone interviews as scheduled~* Be willing and able to provide informed consent~Exclusion Criteria:~* Known or suspected pregnancy~* Contraindication to estrogen use, such as presence or history of:~  * venous thromboembolism~ * Arterial thrombosis~ * Thrombophilia disorders, or known family history of~ * Hypertension~ * Migraine headaches with aura or focal neurologic involvement, or any migraine over age 35 years~* Recent or planned future major surgery which will result in prolonged immobilization during the study period~* Presence or history of severe hepatic disease or liver tumors~* Known or suspected estrogen-dependent neoplasm~* Vaginal bleeding of unknown etiology~* Any cigarette smoking and age over 35 years~* Contraindications to nonsteroidal anti-inflammatory use, such as presence or history of:~  * Gastrointestinal ulcer disease~ * Renal insufficiency or failure~ * Aspirin-induced asthma or hypersensitivity reaction~ * Systemic lupus erythematosus (SLE) and mixed connective tissue disorders~ * Use of anticoagulants~ * Cardiovascular disease~* Use of medications that alter estrogen metabolism, i.e. rifampin, certain anti-seizure medications~* Regular use of an NSAID~* Current diagnosis of menorrhagia, metrorrhagia, symptomatic uterine fibroids, or endometrial polyp~* Hypersensitivity or allergy to any of the components of the estradiol patch~* Use of injectable contraception within 6 months of the start of the study medication~* Delivery or abortion in the previous 4 weeks~* Prior use of LNG-IUD~* Any condition, that in the opinion of the investigator, would contraindicate study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- transdermal estradiol (Type: EXPERIMENTAL): participants will be randomized to transdermal estradiol
- oral naproxen (Type: EXPERIMENTAL): participants will be randomized to oral naproxen
- oral placebo (Type: PLACEBO_COMPARATOR): participants will be randomized to oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete